Drugs that contain Drospirenone; Estetrol

1. List of Nextstellis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7732430 MAYNE PHARMA Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception
Mar, 2025

(1 year, 8 months from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 15, 2026

NCE-1 date: 2025-04-15

Market Authorisation Date: 15 April, 2021

Treatment: Use by females of reproductive potential to prevent pregnancy

Dosage: TABLET;ORAL

More Information on Dosage

NEXTSTELLIS family patents

17

European Union

14

Netherlands

9

Canada

9

United States

7

Germany

7

Spain

6

Denmark

6

Austria

6

Portugal

1

ME

YU

1

Yugoslavia

1

Poland

1

Korea, Republic of

1

Ukraine

1

Luxembourg

1

Brazil

1

Hong Kong

1

Costa Rica

1

Turkey

1

China

1

Japan

1

Belgium

1

Hungary

1

Mexico

1

New Zealand

EA

1

EA

1

Australia

1

Norway

1

South Africa

1

Ecuador

1

Israel

1

Cyprus

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic